|
The Government of Andhra Pradesh today signed a Memorandum of Understanding (MoU) with AstraZeneca India to launch India's first integrated precision oncology ecosystem, bringing together Artificial Intelligence (AI), next generation sequencing (NGS), advanced genomics and the innovation capabilities of Amaravati Quantum Valley (AQV) to transform cancer care. The collaboration aims to establish a comprehensive technology-enabled model that spans the entire patient journey—from early screening and diagnosis to genomic testing, personalised treatment and long-term follow-up—setting a new benchmark for public healthcare innovation and positioning Andhra Pradesh at the forefront of precision medicine in India.
Globally, healthcare systems are adopting AI, genomics and precision medicine to enable earlier diagnosis, improve treatment outcomes and reduce mortality. Through this initiative, Andhra Pradesh is among the first states in the country to systematically integrate these globally proven technologies into its public healthcare system.
Bringing together AstraZeneca's global leadership in oncology, the AI and advanced computing ecosystem of Amaravati Quantum Valley, and Andhra Pradesh's vision of technology-enabled healthcare, the collaboration will create an end-to-end precision oncology platform that supports every stage of cancer care—from AI-enabled screening and diagnosis to biomarker testing, treatment planning and long-term follow-up.
As part of the collaboration, AstraZeneca India will facilitate the deployment of Qure.ai's artificial intelligence-powered chest X-ray solution across selected government healthcare facilities to strengthen the early detection of lung cancer.
A key pillar of the partnership is the establishment of the Integrated Genomic Solutions Centre (IGSC), a first-of-its-kind initiative in Andhra Pradesh that will significantly expand access to advanced genomic diagnostics for cancer patients. The Government of Andhra Pradesh will facilitate the initiative by providing the required infrastructure and institutional support, while AstraZeneca India, together with its scientific and technology partners, will lead implementation by bringing global expertise in precision oncology, biomarker testing and clinical pathway development.
The IGSC will perform next generation sequencing (NGS)-based biomarker testing for lung and breast cancer patients. During the initial phase of the program, AstraZeneca India will facilitate complimentary biomarker testing which will help improving access to advanced diagnostics that are often inaccessible because of cost or limited availability.
Chief Minister of Andhra Pradesh, Nara Chandrababu Naidu, said: "Healthcare across the world is undergoing a fundamental transformation. Artificial intelligence, genomics and data science are changing the way diseases are detected, diagnosed and treated. Our vision is to ensure that these technologies are not confined to a few advanced institutions but become accessible to every citizen through our public healthcare system.
Our partnership with AstraZeneca represents an important milestone in building a predictive, preventive and personalised healthcare ecosystem for Andhra Pradesh. By integrating AI-enabled screening, advanced genomic diagnostics and coordinated patient pathways, we aim to detect cancer earlier, improve treatment outcomes and reduce the burden on thousands of families.
This initiative complements our broader vision of leveraging emerging technologies through programmes such as Sanjeevani, Real Time Governance and Amaravati Quantum Valley to build a healthier, future-ready Andhra Pradesh. It is another step towards making the State a national leader in healthcare innovation while ensuring that innovation ultimately serves people."
Praveen Rao Akkinepally, country president & managing director, AstraZeneca Pharma India Ltd., said: "Cancer care is increasingly moving towards precision medicine, where every patient receives treatment based on the unique biology of their disease. At AstraZeneca, we are committed to transforming cancer outcomes through scientific innovation, early diagnosis, and equitable access to advanced care.
|